The Clinical trials registered in Clinicaltrial.gov that involve ERN Members and Affiliated partners in at least two Member States are listed below.
| Monitoring period | Title | Members and Affiliated Partners | Member State(s) |
|---|---|---|---|
| 2024 | A randomized, double-blind, placebo-controlled phase 3 study of SY-1425 plus azacitidine versus placebo plus azacitidine in newly diagnosed, RARA-positive adult patients with higher-risk myelodysplastic syndrome | AUSL Romagna- Presidio Ospedaliero di Ravenna; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Spedali Civili di Brescia; University Clinical Centre; University Hospital Liège; University Hospital Liège. | Belgium, Italy, Poland. |
| 2024 | A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma (OASIS II) | CHU de Montpellier; Jules Bordet Institute. | Belgium, France. |
| 2024 | A Phase 1b/2 Study of BMS-986158 Monotherapy and in Combination with Either Ruxolitinib or Fedratinib in Participants with DIPSS Intermediate or High Risk Myelofibrosis | AOUI Verona; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Spedali Civili di Brescia; University Clinical Centre. | France, Italy, Poland. |
| 2024 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (frontMIND) | AUSL Romagna- Presidio Ospedaliero di Ravenna; CHU de Lille; Foundation IRCCS Polyclinic San Matteo, Pavia; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; University Hospital Brno; University of Debrecen. | Czechia, France, Hungary, Italy, Poland. |
| 2024 | Treatment of chemo-refractory viral infections after allogenic stem cell transplantation with multi specific T cell against CMV, EBV and AdV: A phase III, prospective, multicenter clinical trial | Leiden University Medical Center; University Hospital Liège. | Belgium, Netherlands. |
| 2024 | Azole-echinocandin combination therapy for invasive aspergillosis. A multicenter pragmatic randomized superiority trial | Erasmus MC: University Medical Center Rotterdam; University Hospital Leuven; University Hospital Liège. | Belgium, Netherlands. |
| 2024 | A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma | General Hospital of Athens "LAIKO"; Maria Sklodowska-Curie National Research Institute of Oncology. | Greece, Poland. |
| 2024 | A Randomized, Double-Blind, A15-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | AOUI Verona; CHU de Limoges; Centro Hospitalar Universitário de Santo António; Hospital Universitari Vall d'Hebron; Medical University of Vienna; Universitair Ziekenhuis Antwerpen; Universitätsklinikum Hamburg-Eppendorf. | Belgium, Germany, Spain, France, Italy, Portugal. |
| 2024 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5) | Aarhus University Hospital; Universitair Ziekenhuis Antwerpen. | Belgium, Denmark. |
| 2024 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises | AOU - University Luigi Vanvitelli; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor. | France, Italy. |
| 2024 | A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises | AOU - University Luigi Vanvitelli; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor. | France, Italy. |
| 2024 | Asciminib Treatment Optimization in ≥ 3rd Line CML-CP. | AOU Policlinico Umberto I - Rome; AOUI Verona; CHU de Montpellier; General Hospital of Athens "LAIKO". | France, Greece, Italy. |
| 2024 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | IRCCS Azienda Ospedaliero-Universitaria di Bologna; Ospedale Papa Giovanni XXIII di Bergamo; Spedali Civili di Brescia; University Hospital Brno. | Czechia, Italy. |
| 2024 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | AOUI Verona; Aarhus University Hospital; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa; University Hospital Leuven. | Belgium, Denmark, Finland, Italy. |
| 2024 | AFFIRM-AL study: A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis. | AOU Policlinico Umberto I - Rome; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; CHU de Limoges; Charité Universitätsmedizin Berlin; Faculty Hospital of Palacky University Olomouc; Foundation IRCCS Polyclinic San Matteo, Pavia; Hospital Universitari Vall d'Hebron; Medical University of Vienna; University General Hospital Attikon; University Hospital Brno; University Hospitals Saint-Luc; Universitätsklinikum Heidelberg. | Belgium, Czechia, Germany, Spain, France, Greece, Italy, Austria. |
| 2024 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM) | Foundation IRCCS Polyclinic San Matteo, Pavia; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna; University Hospital Brno. | Czechia, Spain, Italy, Poland, Austria. |
| 2024 | A Phase II StudyY EVALUATINA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor. | Denmark, France. |
| 2024 | A randomized non comparative phase II study of lacutamab with GEMOX versus GEMOX alone in relapsed/refractory patients with perepheral T-cell lymphoma (KILT) | CHU de Montpellier; Jules Bordet Institute. | Belgium, France. |
| 2024 | Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia | AOU Policlinico Umberto I - Rome; AOUI Verona; Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; General Hospital of Athens "LAIKO"; Jules Bordet Institute; Ordensklinikum Linz Elisabethinen; University Hospital Liege. | Belgium, Denmark, France, Greece, Italy, Austria. |
| 2024 | A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis | AOUI Verona; University Hospital RWTH Aachen. | Germany, Italy. |
| 2024 | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | Aarhus University Hospital; Foundation polyclinic University A. Gemelli - Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Ospedale San Raffaele di Milano; Maria Sklodowska-Curie National Research Institute of Oncology; University of Debrecen; Universitätsklinikum Hamburg-Eppendorf; Universitätsklinikum Leipzig. | Germany, Denmark, Hungary, Italy, Poland. |
| 2024 | Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | AOU Modena; Charité Universitätsmedizin Berlin. | Germany, Italy. |
| 2024 | A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies (BGB-16673-101) | AOUI Verona; Hospital General Gregorio Marañón; Ulm University Medical Center (UUMC). | Germany, Italy. |
| 2024 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) | Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau; Maria Sklodowska-Curie National Research Institute of Oncology; Ospedale Papa Giovanni XXIII di Bergamo; University Hospital Brno; University of Debrecen. | Czechia, Hungary, Italy, Poland, Spain. |
| 2024 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma (EMN29) | AOU Careggi, Florence; AOU Città della Salute e della Scienza di Torino; AUSL Romagna- Presidio Ospedaliero di Ravenna; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; CHU de Lille; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS; Ospedale Papa Giovanni XXIII di Bergamo; Spedali Civili di Brescia. | France, Italy. |
| 2024 | RISE UP (AG348-C-020) : A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease | AORN A Cardarelli; AOU Modena; Assistance Publique Hôpitaux de Marseille; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; CHU de Pointe-à -Pitre/Abymes; CUB-Hôpital Erasme; CUB-Hôpital Erasme; Erasmus MC: University Medical Center Rotterdam; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; IRCCS Ospedale Pediatrico Bambino Gesù- Roma; Riuniti hospitals Villa Sofia-Cervello - Palermo; Universitair Ziekenhuis Antwerpen; University Hospital Liège; University Medical Center Utrecht. | Belgium, France, Italy, Netherlands. |
| 2024 | Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis | AOU Policlinico Umberto I - Rome; ASST Sette Laghi - Ospedale di Circolo, Varese; Hospices Civils de Lyon; Hospital Universitari Vall d'Hebron. | Spain, France, Italy. |
| 2024 | Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Erasmus MC: University Medical Center Rotterdam; Institute of Hematology and Blood Transfusion- Prague. | France, Netherlands, Czechia. |
| 2024 | A phase 3, randomized, double-blind, placebo-controlled study of the efficacy and safety of parsaclisib in participants with primary warm autoimmune hemolytic anemia | Ulm University Medical Center (UUMC); University Hospital Liège. | Belgium, Germany. |
| 2024 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; AOU Policlinico Umberto I - Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University Hospital Leuven; University Hospital Liège; University Hospital Liège. | Belgium, Italy. |
| 2024 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3) | Aarhus University Hospital; University Hospital Leuven. | Belgium, Denmark. |
| 2024 | A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Rituximab or Obinutuzumab Versus Lenalidomide plus Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Faculty Hospital of Palacky University Olomouc; Foundation IRCCS Polyclinic San Matteo, Pavia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna; Ulm University Medical Center (UUMC); University Hospital Leuven. | Belgium, Czechia, Germany, France, Italy, Poland, Austria. |
| 2024 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Foundation polyclinic University A. Gemelli - Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Maria Sklodowska-Curie National Research Institute of Oncology. | Italy, Poland. |
| 2024 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period | Charité Universitätsmedizin Berlin; Copenhagen University Hospital - Rigshospitalet; Hospital Universitari Vall d'Hebron; University Medical Center Utrecht. | Germany, Spain, Netherlands, Denmark. |
| 2024 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; General Hospital of Athens "LAIKO"; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; University Hospital Brno. | Czechia, Spain, Greece, Italy, Poland. |
| 2024 | COVALENT-101: A phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) | AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; IRCCS Ospedale San Raffaele di Milano; Radboud University Medical Center Nijmegen. | Italy, Netherlands. |
| 2024 | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period. | Charité Universitätsmedizin Berlin; Copenhagen University Hospital - Rigshospitalet; Hospital Universitari Vall d'Hebron; University Medical Center Utrecht; Universitätsklinikum Würzburg. | Germany, Spain, Netherlands, Denmark. |
| 2024 | LUSPLUS trial - A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of Luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) | Hospital General Gregorio Marañón; Hospital Universitari Vall d'Hebron; Universitätsklinikum Leipzig; Universitätsklinikum Leipzig. | Germany, Spain. |
| 2024 | A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; University Hospital Leuven. | Belgium, France, Italy. |
| 2024 | Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (ALTAMIRA) | Aarhus University Hospital; Karolinska University Hospital. | Denmark, Sweden. |
| 2024 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway) | Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Foundation IRCCS Polyclinic San Matteo, Pavia; Hospital Universitario Virgen del Rocio; Maria Sklodowska-Curie National Research Institute of Oncology. | Italy, Poland, Spain. |
| 2024 | REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE) | Aarhus University Hospital; Hospital General Gregorio Marañón. | Denmark, Spain. |
| 2024 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) | AOU Città della Salute e della Scienza di Torino; AUSL Romagna- Presidio Ospedaliero di Ravenna; AUSL-IRCCS di Reggio Emilia; Aarhus University Hospital; Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; Copenhagen University Hospital - Rigshospitalet; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Institute of Hematology and Blood Transfusion, Prague; Medical University of Vienna; Ordensklinikum Linz Elisabethinen; Ospedale Papa Giovanni XXIII di Bergamo; Spedali Civili di Brescia; University Hospital Brno; University Hospital Leuven; University Hospital Liège. | Belgium, Czechia, Denmark, France, Greece, Italy, Netherlands, Austria. |
| 2024 | A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain | AOU Federico II - Naples; AOU Policlinico Umberto I - Rome; CHU de Lille; CHU de Limoges; Charité Universitätsmedizin Berlin; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; University Medical Center Utrecht; Universitätsklinikum Heidelberg. | Germany, France, Greece, Italy, Netherlands. |
| 2024 | A phase 3, randomized, double-blind, placebo-controlled multicenter study of Itolizumab in combination with corticosteroids for the initial treatment of acute graft versus host disease | CHU de Lille; University Hospital Leuven; University Hospital Liège. | Belgium, France. |
| 2024 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis. | Denmark, France. |
| 2024 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Charité Universitätsmedizin Berlin; Faculty Hospital of Palacky University Olomouc; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna. | Belgium, Czechia, Germany, Finland, France, Poland, Austria. |
| 2024 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | Gemeinschaftsklinikum Mittelrhein gGmbH; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; IRCCS Ospedale Pediatrico Bambino Gesù- Roma. | Germany, Italy. |
| 2024 | Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1) | AOUI Verona; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor. | France, Italy. |
| 2024 | SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (IRAKLIA) | Foundation IRCCS Polyclinic San Matteo, Pavia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto Scientiï¬co Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS; Ospedale Papa Giovanni XXIII di Bergamo; Riuniti hospitals Villa Sofia-Cervello - Palermo; Spedali Civili di Brescia; University Hospital Brno. | Czechia, Italy. |
| 2024 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) (waveLINE-007) | Foundation polyclinic University A. Gemelli - Rome; Hospital Universitario Virgen del Rocio; IRCCS Ospedale San Raffaele di Milano; Maria Sklodowska-Curie National Research Institute of Oncology. | Italy, Poland, Spain. |
| 2024 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | Aarhus University Hospital; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa. | Denmark, Finland. |
| 2024 | An open label, controlled, randomized study evaluating the benefit of autologous stem cell transplantation after complete Response in frontline setting patients with T Cell Lymphoma (TRANSCRIPT) | CHU de Montpellier; Jules Bordet Institute. | Belgium, France. |
| 2024 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3) | AUSL-IRCCS di Reggio Emilia; CHU de Montpellier; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; Universitätsklinikum Wurzburg. | Czechia, France, Italy, Poland, Spain, Germany. |
| 2024 | A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Erasmus MC: University Medical Center Rotterdam; Institute of Hematology and Blood Transfusion- Prague; Universitätsklinikum Leipzig. | Germany, France, Netherlands, Czechia. |
| 2024 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Foundation polyclinic University A. Gemelli - Rome; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; Ulm University Medical Center (UUMC); University Hospital Brno. | Czechia, Germany, Spain, Italy, Poland. |
| 2024 | An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura | Charité Universitätsmedizin Berlin; Expert Center on coagolopathias and Congenital Anemias; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital General Gregorio Marañón; Institute of Hematology and Blood Transfusion- Prague; Medical University of Vienna; University Medical Center Utrecht. | Bulgaria, Germany, Netherlands, Spain, Czechia. |
| 2024 | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL) | Aarhus University Hospital; Erasmus MC: University Medical Center Rotterdam. | Denmark, Netherlands. |
| 2024 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | CHU de Limoges; Hospital Universitari Vall d'Hebron; Maria Sklodowska-Curie National Research Institute of Oncology; Ulm University Medical Center (UUMC). | Germany, Spain, France, Poland. |
| 2024 | Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases | IRCCS Clinical Institute Humanitas - Rozzano; Spedali Civili di Brescia; Universitätsklinikum Leipzig. | Germany, Italy. |
| 2024 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | Aarhus University Hospital; Universitätsklinikum Heidelberg. | Germany, Denmark. |
| 2024 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) | ASST Sette Laghi - Ospedale di Circolo, Varese; Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Medical University of Vienna; University Hospital Leuven. | Belgium, Denmark, France, Italy. |
| 2024 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2) | Aarhus University Hospital; Jules Bordet Institute. | Belgium, Denmark. |
| 2024 | IMpress trial - A phase II study evaluating the efficacy and safety of imetelstat in patients with HR myelodysplastic syndromes or AML failing HMA-based therapy | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Universitätsklinikum Leipzig; Universitätsklinikum Leipzig. | Germany, France. |
| 2024 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | Aarhus University Hospital; Maria Sklodowska-Curie National Research Institute of Oncology. | Denmark, Poland. |
| 2024 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Ospedale San Raffaele di Milano; Institute of Hematology and Blood Transfusion, Prague; Istituto Scientiï¬co Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS; Maria Sklodowska-Curie National Research Institute of Oncology; Riuniti hospitals Villa Sofia-Cervello - Palermo; Spedali Civili di Brescia; University Hospital Leuven; Universitätsklinikum Freiburg. | Belgium, Czechia, Germany, France, Italy, Poland. |
| 2024 | A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants With Alpha (α)-Thalassemia | AOU S.Luigi Gonzaga; Aghia Sophia Children's Hospital. | Italy, Greece. |
| 2024 | An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3) | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Hospital de Sant Joan de Deu- Hospital de la Santa Creu i Sant Pau. | France, Italy, Spain. |
| 2024 | Phase 3, Interventional, Multicentre, Open-label, Randomized Study Comparing Rituximab Plus Zanubrutinib to Rituximab Monotherapy in Previously Untreated, Symptomatic Splenic Marginal Zone Lymphoma (RITZ) | AOU Siena; ASST Sette Laghi - Ospedale di Circolo, Varese; AUSL Romagna- Presidio Ospedaliero di Ravenna; AUSL-IRCCS di Reggio Emilia; Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Foundation IRCCS Polyclinic San Matteo, Pavia; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Ospedale San Raffaele di Milano; Medical University of Vienna; Riuniti hospitals Villa Sofia-Cervello - Palermo; Spedali Civili di Brescia. | Denmark, Spain, France, Italy, Austria. |
| 2024 | First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | Radboud University Medical Center Nijmegen; Spedali Civili di Brescia. | Italy, Netherlands. |
| 2024 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | AOU Federico II - Naples; CHU de Lille; Faculty Hospital of Palacky University Olomouc; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna; Universitätsklinikum Hamburg-Eppendorf. | Czechia, Germany, France, Italy, Poland. |
| 2024 | First-in-human, open label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell-engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in triple exposed male and female participants aged ≥18 years old with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light-chain amyloidosis (R/R LCA). | IRCCS Clinical Institute Humanitas - Rozzano; Jules Bordet Institute. | Belgium, Italy. |
| 2024 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries (MERLIN) | Aarhus University Hospital; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa. | Denmark, Finland. |
| 2024 | A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy | Academic Medical Center Amsterdam; Istituto Scientiï¬co Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS; Medical University of Vienna; Spedali Civili di Brescia; University Hospital Liège. | Belgium, Italy, Netherlands, Austria. |
| 2024 | Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies SATISFY | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Copenhagen University Hospital - Rigshospitalet; University Medical Center Utrecht. | France, Netherlands, Denmark. |
| 2024 | Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) | Academic Medical Center Amsterdam; Institute of Hematology and Blood Transfusion- Prague; Karolinska University Hospital; Universitätsklinikum Heidelberg. | Germany, Netherlands, Sweden, Czechia. |
| 2024 | Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MARSUN) | CHU de Lille; Jules Bordet Institute. | Belgium, France. |
| 2024 | GenoMed4All : "Improving SCD Classification and Prognosis by AI" / "Genomics and personalized medecine for all through Artificial Intelligence (AI) in Haematological Diseases" | AOU Città della Salute e della Scienza di Torino; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Clinical Institute Humanitas - Rozzano; University Medical Center Utrecht. | Spain, France, Italy, Netherlands. |
| 2024 | A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS) | AO Padua; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Institute of Hematology and Blood Transfusion- Prague; Radboud University Medical Center Nijmegen. | France, Italy, Netherlands, Czechia. |
| 2024 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | Aarhus University Hospital; CHU de Montpellier. | Denmark, France. |
| 2024 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | Aarhus University Hospital; IRCCS Clinical Institute Humanitas - Rozzano. | Denmark, Italy. |
| 2024 | A Phase 3, Randomized, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea | ASST Sette Laghi - Ospedale di Circolo, Varese; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospital Universitari Vall d'Hebron. | Spain, France, Italy. |
| 2024 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1) | AOU Federico II - Naples; ASST Sette Laghi - Ospedale di Circolo, Varese; AUSL Romagna- Presidio Ospedaliero di Ravenna; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Institute of Hematology and Blood Transfusion, Prague; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l. IRCCS; Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Vienna; Ordensklinikum Linz Elisabethinen; Spedali Civili di Brescia; Universitätsklinikum Wurzburg. | Czechia, Spain, France, Italy, Poland, Germany, Austria. |
| 2024 | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2) | AOU Modena; Jules Bordet Institute; Maria Sklodowska-Curie National Research Institute of Oncology. | Belgium, Italy, Poland. |
| 2024 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology; Ulm University Medical Center (UUMC); University Hospital Leuven. | Belgium, Czechia, Germany, Poland. |
| 2024 | A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (ROCKnrol-1) | Aarhus University Hospital; Academic Medical Center Amsterdam; University Hospital Liège; University Hospital Liège; University Hospitals Saint-Luc. | Belgium, Denmark, Netherlands. |
| 2024 | A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) | Institute of Hematology and Blood Transfusion- Prague; Radboud University Medical Center Nijmegen; Ulm University Medical Center (UUMC); Universitätsklinikum Leipzig. | Germany, Netherlands, Czechia. |
| 2024 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Aarhus University Hospital; Hospital General Gregorio Marañón. | Denmark, Spain. |
| 2024 | M24-209: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion | CHU de Limoges; General Hospital of Athens "LAIKO"; IRCCS Azienda Ospedaliero-Universitaria di Bologna. | France, Greece, Italy. |
| 2024 | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS) (EMN33) | AOU Careggi, Florence; AOU Città della Salute e della Scienza di Torino; AUSL-IRCCS di Reggio Emilia; Academic Medical Center Amsterdam; Foundation IRCCS Polyclinic San Matteo, Pavia; General Hospital of Athens "LAIKO"; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical University of Vienna; Ordensklinikum Linz Elisabethinen; Ospedale Papa Giovanni XXIII di Bergamo; Spedali Civili di Brescia. | Greece, Italy, Netherlands, Austria. |
| 2024 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2) | Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospital Universitari Vall d'Hebron; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology. | Czechia, Spain, France, Italy, Poland. |
| 2024 | Glanzmann-NHS: Glanzmann Thrombasthenia Natural History Study | AOU Careggi, Florence; Erasmus MC: University Medical Center Rotterdam; Radboud University Medical Center Nijmegen; University Medical Center Utrecht. | Italy, Netherlands. |
| 2024 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6) | Aarhus University Hospital; Medical University of Vienna. | Denmark, Austria. |
| 2024 | HMB-001: A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia | Assistance Publique Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; University Hospital Leuven; University Medical Center Utrecht. | Belgium, France, Netherlands. |
| 2024 | A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non- Hodgkin Lymphoma (OLYMPIA-4) | ASST Sette Laghi - Ospedale di Circolo, Varese; Erasmus MC: University Medical Center Rotterdam; Spedali Civili di Brescia. | Italy, Netherlands. |
| 2024 | REMARK - A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS) | AOU Careggi, Florence; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospital Universitari Vall d'Hebron; Universitätsklinikum Leipzig; Universitätsklinikum Leipzig. | Germany, Spain, France, Italy. |
| 2024 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; CHU de Lille; HUS Helsinki University Hospital, Hospital District of Helsinki and Uusimaa; Hospital General Gregorio Marañón; Institute of Hematology and Blood Transfusion, Prague; Maria Sklodowska-Curie National Research Institute of Oncology. | Czechia, Denmark, Finland, France, Poland, Spain. |
| 2024 | A phase 2, open-label, randomized, multicenter study to evaluate the safety and efficacy of Axatilimab in combination with Ruxolitinib in participants with newly diagnosed chronic graft-versus-host disease | AOU Città della Salute e della Scienza di Torino; University Hospital Leuven; University Hospital Liège. | Belgium, Italy. |
| 2024 | An Extension Study for Patients Previously Enrolled in Studies with Pelabresib | ASST Sette Laghi - Ospedale di Circolo, Varese; Academic Medical Center Amsterdam; Universitair Ziekenhuis Antwerpen. | Belgium, Italy, Netherlands. |
| 2024 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | ASST Sette Laghi - Ospedale di Circolo, Varese; Aarhus University Hospital; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Hospital Universitari Vall d'Hebron; Ordensklinikum Linz Elisabethinen. | Denmark, Spain, France, Italy, Austria. |
| 2024 | Safety and efficacy of anti-CD123 chimeric antigen receptor-modified autologous T cells (CART123) in patients with relapsed/refractory CD123+ hematologic malignancies. | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; IRCCS Ospedale San Raffaele di Milano; Institute of Hematology and Blood Transfusion- Prague. | France, Italy, Netherlands, Czechia. |
| 2024 | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients | Academic Medical Center Amsterdam; Copenhagen University Hospital - Rigshospitalet; Erasmus MC: University Medical Center Rotterdam; University Hospital Leuven; University Medical Center Utrecht. | Belgium, Netherlands, Denmark. |
| 2024 | A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | AORN A Cardarelli; AOU - University Luigi Vanvitelli; AOU Careggi, Florence; AOU Federico II - Naples; AOU S.Luigi Gonzaga; ASST Sette Laghi - Ospedale di Circolo, Varese; Academic Medical Center Amsterdam; Aghia Sophia Children's Hospital; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; General Hospital of Athens "LAIKO"; University Hospital Leuven; Universitätsklinikum Carl Gustav Carus. | Belgium, Germany, France, Greece, Italy, Netherlands. |
| 2024 | Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia | AORN A Cardarelli; AOU - University Luigi Vanvitelli; AOU S.Luigi Gonzaga; Aghia Sophia Children's Hospital; IRCCS Ospedale Pediatrico Bambino Gesù, Roma. | Italy, Greece. |
| 2024 | A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (XTEND-1) | AOU Careggi, Florence; Assistance Publique Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital de Sant Joan de Déu- Hospital de la Santa Creu i Sant Pau; Hospital de Sant Joan de Déu; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; San Bortolo Hospital - Vicenza. | Spain, France, Italy. |
| 2024 | Haemophilia and Bone Loss - PHILEOS Study (PHILEOS) | Assistance Publique Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; Hospices Civils de Lyon; University Hospitals Saint-Luc. | Belgium, France. |
| 2024 | HAVEN 7 - A phase IIIb, multicentre, open-label, single arm study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of subcutaneous emicizumab in patients from birth to 12 months of age with haemophilia A without inhibitors - Multicentre, international, interventional study. | Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Azienda Ospedaliero-Universitaria di Parma; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospital Universitario Virgen del Rocio; ; Hospital de Sant Joan de Déu; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; University Hospital Leuven. | Belgium, Spain, France, Italy, Netherlands. |
| 2024 | A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) | AO Padua; AOU S.Luigi Gonzaga; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; CHU de Montpellier; Charité Universitätsmedizin Berlin; Foundation IRCCS Polyclinic San Matteo, Pavia; Hospital General Gregorio Marañón; Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen del Rocio; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; IRCCS Ospedale Pediatrico Bambino Gesù- Roma; Universitätsklinikum Heidelberg. | Germany, Spain, France, Italy. |
| 2024 | Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study | AO Padua; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; CUB-Hôpital Erasme; CUB-Hôpital Erasme; Hospital General Gregorio Marañón; Hospital Universitari Vall d'Hebron; Universitätsklinikum Heidelberg. | Belgium, Germany, Spain, France, Italy. |
| 2024 | ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension | AO Padua; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Montpellier; Charité Universitätsmedizin Berlin; General Hospital of Athens "LAIKO". | Germany, France, Greece, Italy. |
| 2024 | ENERGIZE (Agios AG348-C017). A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) | AORN A Cardarelli; AOU Modena; AOU S.Luigi Gonzaga; Academic Medical Center Amsterdam; Aghia Sophia Children's Hospital; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Azienda Ospedaliero-Universitaria S. Anna di Ferrara; Copenhagen University Hospital - Rigshospitalet; Erasmus MC: University Medical Center Rotterdam; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; General Hospital of Athens "LAIKO"; Hospices Civils de Lyon; Hospital Universitari Vall d'Hebron; Hospital Universitario Virgen del RocÃo; University Medical Center Utrecht. | Spain, France, Greece, Italy, Netherlands, Denmark. |
| 2024 | A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). (CROSSWALK-a) | AOUI Verona; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Hospital General Gregorio Marañón; Hospital Universitario Virgen del Rocio. | France, Italy, Spain. |
| 2024 | A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors | AOU Careggi, Florence; Academic Medical Center Amsterdam; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; CHU de Lille; Centro Hospitalar e Universitario de Coimbra, EPE; Hospices Civils de Lyon; University Hospital Leuven; University Hospitals Saint-Luc; University Medical Center Utrecht; Vilnius University Hospital Santaros Klinikos. | Belgium, France, Italy, Lithuania, Netherlands, Portugal. |
| 2024 | A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) | AOUI Verona; Academic Medical Center Amsterdam; Assistance Publique Hôpitaux de Paris- Hôpital Henri-Mondor; Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor; Hospital General Gregorio Marañón; Hospital Universitario Virgen del Rocio. | France, Italy, Netherlands, Spain. |
| 2024 | A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4) | Academic Medical Center Amsterdam; CHU de Lille; Centro Hospitalar e Universitario de Coimbra, EPE; Copenhagen University Hospital - Rigshospitalet; Foundation IRCCS CA'Granda Ospedale Maggiore polyclinic - Milan; Hospices Civils de Lyon; Hospital Universitari Vall d'Hebron; University Hospital Leuven; University Hospitals Saint-Luc; University Medical Center Utrecht. | Belgium, Spain, France, Netherlands, Portugal, Denmark. |
| 2024 | FREEDOM - A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months. | AOU Federico II - Naples; Assistance Publique-Hôpitaux de Marseille; Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades; Azienda Ospedaliero-Universitaria di Parma; ; Hospital de Sant Joan de Déu; IRCCS Ospedale Pediatrico Bambino Gesù, Roma; University Hospital Brno; University Medical Center Utrecht. | Czechia, Spain, France, Italy, Netherlands. |
| 2024 | Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222) (IX-TEND 3003) | Academic Medical Center Amsterdam; Erasmus MC: University Medical Center Rotterdam; University Hospital Leuven; University Medical Center Utrecht. | Belgium, Netherlands. |
| 2024 | A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent | AOU Città della Salute e della Scienza di Torino; AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; CHU de Lille; Spedali Civili di Brescia. | France, Italy. |
| 2024 | A Multicenter, Open-Label Clinical Trial of RVU120 in Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia With or Without NPM1 Mutation (RIVER-52) | AOU Città della Salute e della Scienza di Torino; AOU Ospedali Riuniti "Umberto I - G.M. Lancisi-G. Salesi"; CHU de Lille; Spedali Civili di Brescia. | France, Italy. |